Author: Virax BioLabs Group Limited

Posted Date:

May 26, 2026

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes

Virax BioLabs Group Limited

May 26, 2026
Virax Biolabs’ CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders

Virax BioLabs Group Limited

April 14, 2026
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation

Virax BioLabs Group Limited

March 31, 2026